spironolactone has been researched along with Ventricular Fibrillation in 7 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperaldosteronism was confirmed in 74% of 72 consecutive patients admitted for acute myocardial infarction, in 85% if patients previously treated by an antialdosterone drug or admitted after the acute phase are excluded, and in 96% if patients with cardiac failure are included." | 2.65 | [Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation]. ( Denis, B; Dimitriou, R; Machecourt, J; Page, E; Reboud, JP; Wolf, JE, 1984) |
| "In conclusion, hypokalemia is extremely common in patients presenting with VT/VF, much more so than in patients with CHF alone." | 1.56 | Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study). ( Basil, A; Cooper, JM; Gangireddy, C; Greenberg, RM; Laslett, DB; Whitman, IR; Yesenosky, GA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Laslett, DB | 1 |
| Cooper, JM | 1 |
| Greenberg, RM | 1 |
| Yesenosky, GA | 1 |
| Basil, A | 1 |
| Gangireddy, C | 1 |
| Whitman, IR | 1 |
| Torigoe, K | 1 |
| Tamura, A | 1 |
| Kawano, Y | 1 |
| Shinozaki, K | 1 |
| Kotoku, M | 1 |
| Kadota, J | 1 |
| Zarraga, IG | 1 |
| Dougherty, CM | 1 |
| MacMurdy, KS | 1 |
| Raitt, MH | 1 |
| Alberte, C | 1 |
| Zipes, DP | 1 |
| Denis, B | 1 |
| Dimitriou, R | 1 |
| Machecourt, J | 1 |
| Wolf, JE | 1 |
| Page, E | 1 |
| Reboud, JP | 1 |
| Tourniaire, A | 1 |
| Blum, J | 1 |
| Guyot, R | 1 |
| Madignier, M | 1 |
| Fleming, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antiarrhythmic Effects of Spironolactone in Patients With ICDs[NCT04495712] | Phase 4 | 90 participants (Actual) | Interventional | 2004-07-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients hospitalized for any reason during study follow-up. (NCT04495712)
Timeframe: through study completion, an average of 35 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Spironolactone | 28 |
| Placebo | 24 |
Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item reliable and valid questionnaire, which evaluates HRQOL in heart failure. It quantifies, in a disease-specific fashion, physical limitations, symptoms, quality of life, social interference and self-efficacy. KCCQ provides the calculation of 2 main scores, the overall score and the clinical summary score, which includes functional status, social limitation and quality of life domains scores. Range 0-100, higher scores represent higher HRQOL. (NCT04495712)
Timeframe: through study completion, an average of 35 months
| Intervention | score on a scale (Mean) |
|---|---|
| Spironolactone | 57.35 |
| Placebo | 68.67 |
Patient Concerns Assessment (PCA) is a symptom checklist that measures physical symptoms and fears that are common after ICD implantation. The PCA is a disease-specific instrument for ICD QOL, symptoms, and distress, with a reliability of ( = 0.88). Range 0-44, a higher score reflects more concerns and fears. (NCT04495712)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Spironolactone | 22.15 |
| Placebo | 18.42 |
Short Form Health Survey adapted for veterans (SF36V) is a 36 item questionnaire that measures general physical and mental health [17]. The SF36V is a reliable and valid questionnaire, containing eight constructs of health status: physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), general health perceptions (GH), energy/vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). These eight dimensions can be summarized numerically into two scores, the physical component summary (PCS) and the mental component summary (MCS). Range 0-100 higher score is better Health Related Quality of Life (HRQOL). We are reporting the Mental Component Summary score at 12 months here. (NCT04495712)
Timeframe: 12 months after enrollment
| Intervention | score on a scale (Mean) |
|---|---|
| Spironolactone | 54.87 |
| Placebo | 63.31 |
Time to first documented ICD therapy for ventricular tachycardia or ventricular fibrillation after randomization (NCT04495712)
Timeframe: through study completion, an average of 35 months
| Intervention | months (Median) |
|---|---|
| Spironolactone | 8.8 |
| Placebo | 12.3 |
The right ventricular effective refractory period (ERP) will be measured at 3 month in patients enrolled at the Portland VA Medical Center by single extra stimuli via their implanted defibrillator. The ERP is defined as the shortest paced beat coupling interval that fails to produce ventricular capture after a baseline stable pacing train. (NCT04495712)
Timeframe: measured 3 months after randomization
| Intervention | milliseconds (Mean) |
|---|---|
| Spironolactone | 294.2 |
| Placebo | 278.3 |
1 review available for spironolactone and Ventricular Fibrillation
| Article | Year |
|---|---|
Use of nonantiarrhythmic drugs for prevention of sudden cardiac death.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Comorbidity; Death, Sudden, Cardia | 2003 |
2 trials available for spironolactone and Ventricular Fibrillation
| Article | Year |
|---|---|
The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
Topics: Aged; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Disease-Free S | 2012 |
[Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation].
Topics: Acute Disease; Adult; Aged; Anti-Arrhythmia Agents; Canrenoic Acid; Clinical Trials as Topic; Female | 1984 |
4 other studies available for spironolactone and Ventricular Fibrillation
| Article | Year |
|---|---|
Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study).
Topics: Aged; Cardiomyopathies; Case-Control Studies; Diarrhea; Diuretics; Female; Heart Failure; Humans; Hy | 2020 |
Upright T waves in lead aVR are associated with cardiac death or hospitalization for heart failure in patients with a prior myocardial infarction.
Topics: Age Factors; Aged; Anterior Wall Myocardial Infarction; Chi-Square Distribution; Death, Sudden, Card | 2012 |
[Myocardial hyperexcitability in decompensated cardiopathies. Effect of spironolactone].
Topics: Cardiac Complexes, Premature; Dehydration; Digitalis Glycosides; Diuresis; Diuretics; Heart Failure; | 1969 |
Heart failure and cardiac arrhythmias.
Topics: Arrhythmia, Sinus; Arrhythmias, Cardiac; Coronary Disease; Digoxin; Diuretics; Electroconvulsive The | 1974 |